1
|
Thieblemont C, Clausen MR, Balari AS, Zinzani PL, Fox CP, Kim SY, Vindelov SD, Lugtenburg P. PHASE 3 TRIAL (GCT3013‐05) OF EPCORITAMAB VERSUS STANDARD OF CARE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.162_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Thieblemont
- Assistance Publique & Hôpitaux de Paris (APHP) Hopital Saint‐Louis Université de Paris Hemato‐Oncology Department Paris France
| | - M. R. Clausen
- Vejle Hospital Department of Hematology Vejle Denmark
| | - A. S. Balari
- Institut Català d'Oncologia‐Hospital Duran i Reynals IDIBELL Universitat de Barcelona Hospitalet del Llobregat Department of Hematology Barcelona Spain
| | - P. L. Zinzani
- Lymphoma and Chronic Lymphoproliferative Syndromes Unit Institute of Hematology "L. e A. Seràgnoli," University of Bologna Department of Experimental Diagnostic and Specialty Medicine Bologna Italy
| | - C. P. Fox
- Nottingham University Hospitals NHS Trust UK Department of Clinical Haematology Nottingham UK
| | - S. Y. Kim
- AbbVie, Clinical Development North Chicago Illinois USA
| | | | - P. Lugtenburg
- On behalf of the HOVON/Lymphoma Working Group Erasmus MC Cancer Institute Department of Hematology Rotterdam Netherlands
| |
Collapse
|